Literature DB >> 2747593

An attempt to use a common staging system in rhabdomyosarcoma: a report of an international workshop initiated by the International Society of Pediatric Oncology (SIOP).

C Rodary1, F Flamant, S S Donaldson.   

Abstract

One hundred medical records of children with rhabdomyosarcoma were reviewed independently by ten European and American specialists primarily concerned with pediatric cancer patients. Each specialist assessed the stage of disease using a pre-treatment staging system (International Society of Pediatric Oncology-Union Internationale Contre le Cancer TNM [SIOP-UICC TNM] and a post-surgical staging system (Inter-group Rhabdomyosarcoma [IRS] grouping system). These two prognostic systems are based on different criteria, and there is no simple correspondence between them. The reliability of the two systems, based on patients' characteristics extracted from medical records, was similar and satisfactory (Kappa index: 0.78 and 0.82 with the TNM system and with the IRS system, respectively). Nevertheless, the IRS grouping system, which considers a primary method of treatment: Surgery, is dependent upon the surgeon, the institution, and the current concept of treatment. We believe that the TNM system provides the best description of extent of disease and should be used for determining therapeutic options and comparing therapeutic results.

Entities:  

Mesh:

Year:  1989        PMID: 2747593     DOI: 10.1002/mpo.2950170308

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  7 in total

Review 1.  Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group.

Authors:  Jacquelyn N Crane; Wei Xue; Amira Qumseya; Zhengya Gao; Carola A S Arndt; Sarah S Donaldson; Douglas J Harrison; Douglas S Hawkins; Corinne M Linardic; Leo Mascarenhas; William H Meyer; David A Rodeberg; Erin R Rudzinski; Barry L Shulkin; David O Walterhouse; Rajkumar Venkatramani; Aaron R Weiss
Journal:  Pediatr Blood Cancer       Date:  2022-03-06       Impact factor: 3.838

2.  Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma.

Authors:  L Diller; E Sexsmith; A Gottlieb; F P Li; D Malkin
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 3.  The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore?

Authors:  Frederick B Ruymann
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

Review 4.  Optimal management strategies for rhabdomyosarcoma in children.

Authors:  David Walterhouse; Andrea Watson
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

5.  Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol.

Authors:  Ewa Koscielniak; Bernd Blank; Christian Vokuhl; Bernarda Kazanowska; Ruth Ladenstein; Felix Niggli; Gustaf Ljungman; Rupert Handgretinger; Guido Seitz; Jörg Fuchs; Birgit Fröhlich; Monika Scheer; Rüdiger Wessalowski; Irene Schmid; Monika Sparber-Sauer; Thomas Klingebiel
Journal:  Cancers (Basel)       Date:  2022-02-11       Impact factor: 6.639

6.  DNA ploidy and proliferative activity (S-phase) in childhood soft-tissue sarcomas: their value as prognostic indicators.

Authors:  F K Niggli; J E Powell; S E Parkes; K Ward; F Raafat; J R Mann; M C Stevens
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

7.  Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.

Authors:  Thibault Butel; Marie Karanian; Gaelle Pierron; Daniel Orbach; Dominique Ranchere; Nathalie Cozic; Louise Galmiche; Aurore Coulomb; Nadège Corradini; Brigitte Lacour; Stéphanie Proust; Florent Guerin; Hélène Boutroux; Angélique Rome; Ludovic Mansuy; Cécile Vérité; Anne-Sophie Defachelles; Franck Tirode; Veronique Minard-Colin
Journal:  Cancer Med       Date:  2020-02-22       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.